OncoMatch/Clinical Trials/NCT05256641
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Is NCT05256641 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Acalabrutinib for diffuse large b-cell lymphoma.
Treatment: Acalabrutinib — This phase Ib/II trial studies the side effects and efficacy of maintenance acalabrutinib following cellular therapy in treating patients with large B-cell lymphoma at very high risk of the cancer coming back. Acalabrutinib is a small molecular inhibitor that may interfere with the ability of cancer cells to grow and spread.
Check if I qualifyExtracted eligibility criteria
Cancer type
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: BCL2 rearrangement
Required: BCL6 rearrangement
Required: MYC rearrangement
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: autologous stem cell transplant
Patients undergoing autologous stem cell transplantation (ASCT)
Must have received: CAR-T cell therapy
any Food and Drug Administration (FDA)-approved chimeric antigen receptor (CAR) T-cell therapy product
Must have received: allogeneic hematopoietic cell transplantation
Patients undergoing allogeneic hematopoietic cell transplantation (alloHCT) for large B-cell lymphoma
Lab requirements
Blood counts
Absolute neutrophil count (ANC) > 500/uL; Platelets > 50,000/uL independent of transfusions; Hemoglobin > 8 g/dL independent of transfusions
Kidney function
Creatinine clearance >= 60 mL/min based on Cockcroft-Gault glomerular filtration rate (GFR) and serum creatinine (Cr) <= 1.8 mg/dL
Liver function
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 3 x upper limit of normal (ULN); Total bilirubin <= 1.5 x ULN, unless directly attributable to Gilbert's syndrome
Cardiac function
Left ventricular ejection fraction >= 50%
Absolute neutrophil count (ANC) > 500/uL; Platelets > 50,000/uL independent of transfusions; Hemoglobin > 8 g/dL independent of transfusions; Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <= 3 x upper limit of normal (ULN); Total bilirubin <= 1.5 x ULN, unless directly attributable to Gilbert's syndrome; Creatinine clearance >= 60 mL/min based on Cockcroft-Gault glomerular filtration rate (GFR) and serum creatinine (Cr) <= 1.8 mg/dL; Left ventricular ejection fraction >= 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCLA / Jonsson Comprehensive Cancer Center · Los Angeles, California
- University of California Davis Comprehensive Cancer Center · Sacramento, California
- University of Oklahoma · Oklahoma City, Oklahoma
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify